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Abstract: The antibacterial properties of the excretions/secretions of the medicinal maggot, 
L. sericata have long been known and the effectiveness of maggot debridement therapy in 
relation to the clearance of bacteria from the surface of wounds has been the source of 
much research over recent years. Less well known however, are the antifungal properties of 
L. sericata ES. Here we show by means of the colony forming unit assay and optical density 
assays, that L. sericata native excretions/secretions possess significant antifungal properties 
and appears to possess a highly heat stable, freeze/thaw and lyophilisation resistant 
antifungal component. We also show that the antifungal activity present in the native 
excretions/secretions consists of a number of antifungal components present in three 
fraction masses consisting of >10 kDa, 10 – 0.5 kDa and <0.5 kDa, with the greatest level of 
activity being seen in the <0.5 kDa fraction.  
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Introduction. 
The larval stage of the common green bottle, Lucilia (Phaenicia) sericata (Diptera: 
Calliphoridae), is one of the few members of Diptera that can be applied clinically to chronic 
wounds (1). Maggot debridement therapy (MDT) using L. sericata larvae is now considered a 
viable option for the treatment of certain chronic wounds (2), with the secretions from L. 
sericata having been shown to possess a number of digestive proteases, including serine 
proteases (3, 4) and collagenase (5), which contribute to the debridement of chronic 
wounds allowing healing to take place (6). 
Although in modern medicine, MDT is used primarily for the debridement of chronic 
wounds, there are other associated advantages which go beyond the removal of necrotic 
tissue. As far back as the Napoleonic wars, field hospitals began reporting soldiers with non-
infected, maggot-infested battle wounds showing accelerated healing and no signs of 
infection (7). While there is still much debate as to the precise mechanisms involved in 
wound healing, the antibacterial properties for L. sericata have been thoroughly 
investigated and many antibacterial factors described (8-13).  
It had been suggested that some antimicrobial activity may be attributed to the 
process of debridement, during which ingested bacteria are eradicated as they pass through 
the alimentary tract of the maggot (14). More recent investigations into this activity have 
focused on discerning the identities of the antibacterial components present in the 
excretions/secretions (ES) of L. sericata. Such investigations are driven in part by the 
emergence of microorganisms resistant to conventional therapies, such as methicillin 
resistant Staphylococcus aureus. Recent studies into L. sericata secretions using separation 
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techniques, such as ultrafiltration, have revealed the presence of two antibacterial moieties; 
one 0.5 - 0.3 kDa, heat-stable, protease resistant antibacterial compound and a <0.5 kDa 
component with activity against MRSA (8). These findings suggest that the 
inhibition/extermination of bacteria can occur outside the maggot digestive system and may 
contribute to their ability to thrive on carrion in nature (15). 
In their natural environment, maggots have to compete with several decomposers, 
including fungi, as well as bacteria. Although there is an extensive volume of literature 
available on the antibacterial properties of L. sericata larvae, the antifungal properties have 
attracted considerably less attention, comprising, to our knowledge thus far, of only three 
reports. One showing activity against the agricultural pathogens Fusarium sambucinum and 
Fusarium verticillioides (16), another demonstrating activity of a novel antifungal peptide, 
lucimycin, against the agricultural pathogens F. graminearum and Phytophthora parasitica, 
along with some opportunistic fungal pathogens, including Aspergillus fumigatus and 
Candida albicans (17) and  the other demonstrating activity against Trichophyton terrestre, a 
cause of some superficial fungal infections (18).  
Fungal infections which are unresponsive to conventional antifungal therapies are 
becoming an increasing problem in a clinical setting. Candida species for example represent 
a significant cause of morbidity in patients with chronic conditions (19) with Candida 
albicans accounting for >50% of fungal species isolated from infected wounds, with other 
species of Candida accounting for around 19% (20). Identifying new antifungal agents which 
can be used in a clinical setting, perhaps systemically to treat fungal infections unresponsive 
to conventional therapy is therefore of growing importance. 
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This paper describes the detection of, and preliminary investigations on antifungal activity 
found in L. sericata larval native excretions/secretions (nES).  
 
Materials and Methods. 
Larvae. 
 Sterilised L. sericata eggs were supplied in saline by Biomonde®, Bridgend, UK in 
plastic vials and allowed to hatch at 30OC. Hatchlings were then immediately treated as first 
instar (L1) larvae.  Sterile late L2 and L3 L. sericata larvae were supplied by Biomonde®, 
Bridgend, UK in petri dishes on growth media.  
Microorganisms. 
 Candida albicans SC5134 and Saccharomyces cerevisiae (turbo yeast, Gert strand AB) 
were obtained from the College of Science, Swansea University. C. krusei (Issatchenkia 
orientalis) 6258, C. maltosa 28140 and Saccharomyces boulardii MYA-796 were purchased 
from the ATCC®, Middlesex, UK. All strains were cultured on Sabouraud dextrose agar for 24 
hours at 37OC prior to testing. 
Chemicals. 
 All chemicals used were purchased from Sigma-Aldrich, Dorset, UK, unless stated 
otherwise. 
Collections of larval secretions. 
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 Collection of L. sericata ES was modified from the method previously described by 
Bexfield et al., (8) as described in the supplementary methodology material.  
Unless stated as L1, all experiments were undertaken using secretions collected from late 
L2/L3 larvae. 
Size fractionation of larval secretions. 
 Fractionation of nES took place sequentially. Firstly, 5 ml aliquots of nES were 
filtered through an Amicon Ultra 10 kDa molecular weight cut off (MWCO) centrifugal filter 
(Millipore UK Ltd., Herefordshire, UK) at 4,000 g. Five hundred µl of sterile Milli-Q water 
were added to the retentant and spun for 15 minutes to ensure total volume (i.e. 5 ml) <10 
kDa materials were filtered. The unfiltered ES was then reconstituted to its original volume 
in sterile Milli-Q water and retained as the >10 kDa ES fraction (ES>10). The filtrate was 
passed through a 0.5 kDa MWCO membrane (Sterlitech Corp., WA, USA) in an Amicon 
stirred ultrafiltration cell (Millipore UK Ltd., UK) under ≤75 PSI at 4OC until approximately 0.5 
- 1 ml <10 kDa ES remained. This material was reconstituted to its original volume (5 ml) in 
sterile Milli-Q water and retained for testing as a 10-0.5 kDa ES fraction (ES10-0.5). The filtered 
material was retained as a <0.5 kDa ES fraction (ES<0.5). All fractions were filter sterilised 
through a 0.2 µm filter and stored at -20OC prior to analysis. 
Detection of antifungal activity. 
Colony forming unit (CFU) assay for the detection of antifungal activity. 
 To determine the antifungal activity of L. sericata ES, C. albicans was grown as 
previously described and prepared as recommended by the CLSI M27-A3 document and 
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EUCAST definitive document (EDef 7.2 revision for the determination of broth dilution 
minimum inhibitory concentrations of antifungal agents for yeasts). Briefly, a single colony 
of cultured C. albicans was suspended in 300 µl of sterile Milli-Q water, and mixed for 15 
seconds on a vortex mixer. The cell density was adjusted to 5 x 106 cells/ml and 40 µl of 
inoculum were incubated with 360 µL ES (nES, ES>10, ES10 – 0.5 and ES<0.5) and 40 µl 10-fold 
concentrated SDB prepared in 200 mM HEPES, pH 8.5 for 24 hours at 37oC, whilst being 
agitated. For controls, the fungal inoculum was replaced with sterile Milli-Q water (negative 
growth control) or amphotericin B [4µg/ml] (positive antifungal control). For the positive 
growth control, ES was replaced with sterile Milli-Q water. After the first incubation, each 
sample was diluted 1:700 in sterile PBS and 5µl aliquots spread onto Sabouraud dextrose 
agar plates. The plates were then incubated for a further 24 hours at 37OC before the 
number of colonies on each plate were counted. Each assay was carried out in triplicate and 
the experiment repeated at least three times. 
Optical density (OD) assay for the detection of antifungal activity. 
The OD assay was a modification of the method originally described by Thomas et 
al., (21) and details are elaborated in the supplementary materials section. For controls, ES 
was replaced with sterile Milli-Q water (positive growth control) amphotericin B at a 
concentration of 4 µg/ml (positive antifungal control). For negative growth controls, 50 µl of 
4x concentrated SDB were incubated with 150 µl sterile Milli-Q water. To check for sterility 
of the ES samples, 150 µl of 0.2 µm filtered ES were incubated with 50 µl of 4x concentrated 
SDB. All tests were carried out in triplicate and repeated at least three times. For its ease of 
application, the OD assay was chosen as the primary assay for the detection of antifungal 
activity for all subsequent experiments. 
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Survival Index (SI). 
 Antifungal activity was quantified using the survival index as described previously by 
Bexfield et al. (8). A sample SI of ≤25% was deemed to be the cut-off point to indicate 
antifungal activity. All SI values represent percentage growth of untreated fungal control 
cells which had a growth rate of 100%. 
Physiochemical properties of L. sericata ES. 
 The thermal stability of L. sericata antifungal activity present in nES and ES<0.5 was 
assessed by subjecting samples to heating, freezing/thawing and storage at room 
temperature. For heat inactivation, 1 ml aliquots of nES were placed in sealed microfuge 
tubes in a heating block and incubated at 50OC, 75OC and 100OC for 15, 30 and 60 minutes. 
For heat treatment of ES<0.5, 1ml aliquots of ES<0.5 were incubated at 50
OC, 75OC and 100OC 
for 60 minutes. To determine thermal stability, 1 ml aliquots of nES and ES<0.5 were subject 
to 10 cycles of freezing to -80OC and rapid thawing to 37OC. To further assess the thermal 
stability of L. sericata nES, several 1 ml aliquots of nES and ES<0.5 were placed in sealed 
microfuge tubes and left at room temperature for up to 14 days. Following treatment, all 
samples were cooled to 4OC for 24 hours and then stored at -20OC until testing. 
ES<0.5 stability was also investigated after lyophilisation. Ten ml aliquots of sterile -
ES<0.5 were placed in a 30 ml universal container and covered with punctured aluminium foil. 
Samples were then frozen to -80OC for 30 minutes before being placed in a freeze drier 
cooled to -20OC and allowed to completely lyophilise under vacuum. For reconstitution, 
lyophilised samples were heated to 37OC for 30 minutes and then 1ml sterile Milli-Q water 
at 37OC was added. Samples were then vigorously vortexed before being passed through a 
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0.2 µm filter to remove any particulates and to sterilise the sample prior to being bio-
assayed.  
Statistical testing. 
 All experiments were repeated in triplicate at least three times. Data demonstrating 
differences in SI represent the mean % of fungal growth from each experiment compared to 
100% growth of the positive control. All error bars express the arithmetic mean of three 
repeats, ± S.E.M. Differences between sample absorbance at t0 and t mid-log were assessed 
for significance by stacking all experimental data (omitting outliers) with n = ≥6 in all 
experiments. The two-tailed unpaired Students t-test was then used with P ≤0.05 being 
determined to be significant. 
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Results 
Detection of antifungal activity in L. sericata native larval secretions. 
 The CFU assay demonstrated that L. sericata ES possess antifungal capabilities in 
nES, ES10-0.5 and ES<0.5 fractions. Incubation of C. albicans with ES>10 did not show antifungal 
activity and an increase in CFUs was observed (Figure 1a). Compared to the growth of 
control C. albicans (Figure 1b), fungal growth was found to be significantly reduced when 
exposed to nES (Figure 1c), as well as the ES fraction between 10 kDa and <0.5 kDa (Figure 
1a), with fungal cells subjected to ES<0.5 showing the greatest reduction of CFUs (Figure 1d). 
Antifungal activity was also detected in nES by the OD assay. Figure 2 shows that nES 
inhibits the growth of both C. albicans and S. cerevisiae, with C. albicans exhibiting growth 
inhibition for up to 25 hours (Figure 2a). C. Krusei, C. maltosa, S boulardii and S. cerevisiae 
remained inhibited for the entire duration of the assay (Figure 2b - e). No fungal inhibition 
was seen during treatment of C. albicans with L1 nES (Figure 2f). 
Analysis of physiochemical properties of antifungal activity in nES. 
 The antifungal components of L. sericata nES were found to be remarkably thermally 
stable (Figure 3) retaining activity across all temperatures investigated. Interestingly, activity 
was found to significantly increase after treatment at 50OC for 15, 30 and 60 minutes and 
there was found to be no significant difference in nES activity when heated to 100OC for 15 
minutes, but there was a very highly significant increase in activity after treatment of nES at 
100OC for 60 minutes. These findings indicate that nES becomes more active after exposure 
to higher temperatures for longer periods of time. The antifungal activity of nES was also 
stable after repeated freeze-thawing, retaining significant antifungal activity after ten such 
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cycles (Figure 4). Although there was a slight decrease in the SI between untreated nES and 
nES which had been repeatedly frozen and thawed, there was no significant difference in 
the activity between the two samples (P >0.05). Antifungal activity was also retained by L. 
sericata nES after storage at room temperature for 24 hours, 48 hours, 7 days and 14 days 
(Figure 4). However storage of nES for 14 days at room temperature did show a significant 
increase in antifungal activity.  
Determination of antifungal activity in L. sericata ES fractions. 
Incubation with L. sericata ES fractions revealed that there was significant inhibition 
of fungal growth against all fungal species tested (Figure 5a). Although all fungal species 
were inhibited at t mid-log, there were changes in growth profiles of different fungal 
species. For example, both ES>10 and ES10-0.5 (Figure 5b) were able to inhibit C. albicans 
growth at t mid-log. However, growth increased at a more rapid rate after 20 hours of 
incubation in the ES10-0.5 sample whereas in the sample incubated with ES>10 a small increase 
in fungal growth was seen after 25 hours. Strong antifungal activity was found in the ES<0.5 
fraction (Figure 5c), often comparable to the activity seen in unfractionated nES, but 
stronger than the activity detected in the ES>10 fraction, as indicated by the lower SI values 
(Figure 5a). Although there was no significant difference in activity between ES<0.5 and ES10-
0.5 treated C. krusei and S. cerevisiae (P >0.05), ES<0.5 was found to inhibit fungal growth for a 
longer period of time than the ES10-0.5 fraction (Figure 5b).  
Analysis of physiochemical properties of antifungal activity present in ES<0.5. 
 Thermal stability testing of the ES<0.5 fraction revealed that very strong antifungal 
activity was maintained after heating between 50OC and 100OC for 60 minutes as well as 10 
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cycles of freezing and thawing and this activity significantly increased after 14 days storage 
at room temperature (Figure 6). However, all fractions of ES<0.5 exposed to different 
conditions still retained the potent activity shown in untreated ES<0.5 (Figure 6). 
 
 
Lyophilisation of ES<0.5.   
ES<0.5 also appeared to retain significant antifungal activity after lyophilisation, with 
lyophilised ES<0.5 reconstituted in Milli-Q water (x10 concentrated) completely inhibiting C. 
albicans growth for up to 30 hours (Figure 6). 
Determination of antifungal activity in L. sericata L1 ES fractions. 
Following incubation with all L. sericata L1 ES fractions, there was found to be no 
significant inhibition of fungal growth against C. albicans (supplementary material figures 1 
and 2), indicating that neither L1 ES>10, L1 ES10-0.5, or L1 ES<0.5 were able to inhibit normal C. 
albicans growth.  
Discussion 
The antimicrobial properties of many insects including maggot ES have been widely 
demonstrated against numerous species of bacteria (9, 11, 22), viruses (23) and fungal 
pathogens (16-18), although to our knowledge, this is the first time that antifungal activity 
against several Candida and saccharomyces spp. has been demonstrated and investigated in 
L. sericata nES and its fractions (according to molecular weight). 
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In this investigation, we demonstrate the antifungal activities of L. sericata larval nES 
and ES<0.5 by means of the CFU and OD assay. The findings suggest that there may be a 
number of antifungal components present in L. sericata nES that contribute to the high level 
of activity seen in both assays. Most significantly, this activity includes the presence of at 
least one potent antifungal compound with a low Mr of <0.5 kDa.  
Considering that a number of low-Mr antimicrobial components have previously 
been isolated from other Diptera species, such as 1-lyso-phosphatidylethanolamine (451 Da) 
from Musca domestica (24) and p-hydroxybenzoic acid (138 Da), p-hydroxyphenylacetic acid 
(152 Da) and cyclo propro (194 Da) (10) from L. sericata, it is possible that low-Mr antifungal 
compounds may also be produced by L. sericata.  
  Using the OD assay, a high degree of antifungal activity was detected in all ES 
fractions. The activity seen in the higher molecular weight fractions of ES>10 and ES10-0.5 is 
most likely due to the presence of large (>0.5 kDa) antifungal molecules/peptides, perhaps 
including the recently reported lucimycin (17). The activity seen in these fractions could also 
be derived from other broad spectrum antimicrobial peptides. Drosomycin, isolated from 
Drosophila melanogaster (25) is one such antimicrobial peptide which shows activity against 
fungi and bacteria. The antifungal activity seen in the ES<0.5 fraction however, is most 
certainly due to a novel, smaller Mr compound of molecular weight of <0.5 kDa. 
The high level of activity suggested by the OD assay can be demonstrated by the 
presence of negative SI values. In this study, we have presented a number of data with 
negative SI values, which were typically associated with samples demonstrating antifungal 
activity. These negative SI values resulted from a decrease in sample absorbance, below its 
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starting optical density. Decreases in absorbance due to aberration in instrumentation were 
ruled out by measuring the mean change in absorbance in each well over 18 hours at 30OC 
using a 2x diluted ES10-0.5 sample. This revealed that there was a mean increase in 
absorbance of 0.0 ± 0.0 (n = 192, CI = 4.4%) which could be attributable to the plate reader. 
Decreases in absorbance (like those seen when fungi were exposed to ES fractions) however 
were not observed. It is possible that the decreases in absorbance seen are associated with 
lysis of fungal cells and this could be confirmed following detailed analysis of the mode of 
action of the purified antifungal compounds present. 
Differences observed between the CFU and OD assays can be explained by the 
nature of the different assays. For instance, in the CFU assay, C. albicans is incubated in the 
presence of nES or its fractions. These were then removed to allow growth to occur on an 
agar plate. Therefore, the CFU assay measures colony growth after the first incubation stage 
which takes place in the presence of the antifungal compound/test sample. Thus, during the 
second 24 hour growth period on the agar plate, any suppressive growth components which 
the fungi are exposed to during the first incubation stage are removed (through dilution) 
and fungal growth appears to resume. 
The OD assay however, in which the antifungal agents are present during the 
complete growth period appears to better demonstrate fungal growth kinetics during the 
first incubation stage of the CFU assay, as fungal growth can be monitored within the first 
24 hours. Our data suggest that both the ES>10 and ES10-0.5 fractions may be fungistatic in 
nature against C. albicans. Strong antifungal activity was seen during (OD assay) and 
following (CFU assay) treatment of fungal cells with the ES<0.5 fraction with a 100% reduction 
of fungal cells in the CFU assay, demonstrating fungicidal properties within the ES<0.5 
Page 14 of 32
Wound Repair and Regeneration
Manuscript under review - CONFIDENTIAL
This article is protected by copyright. All rights reserved.
15 
 
fraction. Although the exact mechanisms of the antifungal components in this fraction 
require further investigation, the level of antifungal activity in both assays is clearly greater 
in the ES<0.5 fraction than the ES>10 and ES10-0.5 fractions. For this reason, the ES<0.5 fraction 
was chosen for further investigation.  
 Thermal stability testing of L. sericata nES and ES<0.5 revealed that antifungal activity 
in both was retained despite excessive heating, freezing/thawing and storage at room 
temperature. Heat-stable antibacterial compounds have previously been described in L. 
sericata nES (8) and the perseverance of activity after heating indicates the presence of a 
heat stable antifungal compound in the L. sericata ES<0.5 fraction. This finding however is not 
uncommon, as several peptide and non-peptide based heat stable antifungal compounds 
have been identified in nature, including a broad-spectrum proteinaceous antifungal 
compound produced by Lactobacillus coryniformis (26) and an antimicrobial, β-alanyl-
tyrosin (27).  
Interestingly, the antifungal activity of nES in this study appeared to increase after 
heating to 50OC for 15 minutes compared to untreated nES, a finding also reported by 
Bexfield et al., (8) who attributed this increase in activity to the abrogation of inhibition 
complexes and enhanced activation of the antibacterial factor. Further heating of nES also 
appeared to increase the antifungal activity, with nES also remaining stable after rapid 
freezing and thawing, as well as after prolonged incubation at room temperature. These 
findings support the view that there are small (<0.5 kDa) non-proteinaceous antifungal 
components present in nES.  
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Strong antifungal activity was also retained by ES<0.5 after lyophilisation. Given that 
ES<0.5 appears to retain antifungal activity after freezing, it is perhaps not surprising that 
activity remains after lyophilisation. However the fact that the compound still retains 
activity after all water has been removed from the sample suggests that the compound is 
highly stable when subject to a variety of extreme treatments. 
We also discovered that first instar larval nES possesses no detectable antifungal 
activity. This was surprising, considering that in nature, oviposition of L. sericata eggs occurs 
primarily on carrion and decaying organic matter (15). Our finding that sterile late L2 and L3 
larvae secrete strong antifungal components may suggest that L sericata larvae do not 
possess these antifungal components within the first few hours of hatching. L. sericata 
larvae do however appear to be resistant to cuticle degradation by fungal proteases, while 
adult L sericata promptly die when exposed to sporulating fungi (28). It may be that during 
hatching, the protection provided by the cuticle is adequate in the initial stages of cadaver 
colonisation, with the excretion/secretion of antifungals coinciding with the fungal 
colonisers becoming more established. 
Although the antibacterial properties of L. sericata ES have long been known, the 
antifungal properties have received less attention. Here we show the robust activity of L. 
sericata nES and its fractions against several species of fungi, including C. albicans. Further 
work on the isolation and purification of the active component(s) of the ES<0.5 fraction is 
currently being undertaken with the aim of identifying and chemically defining the small, 
low Mr antifungal found in L. sericata excretions/secretions. Once we have purified and 
isolated the antifungal compound its activity will be assessed against a greater range of 
fungal pathogens and MIC testing will be undertaken. 
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Figure Captions 
Figure 1. Antifungal activity of L. sericata nES and its fractions assessed by means of the CFU assay. 
(A) Percentage growth of C. albicans following incubation with L. sericata nES, ES10-0.5 and ES<0.5 was 
found to be reduced, suggesting significant antifungal activity (P <0.05) as calculated by the CFU 
assay. Incubation of C. albicans with ES>10 however resulted in a significant increase in the number of 
CFUs; * = P <0.05, ** = P <0.005, *** = P <0.001; n = 9. (B) Positive growth control (normal C. 
albicans colony growth). (C) CFU growth following incubation with nES. (D) CFU growth following 
incubation with the ES<0.5 fraction. 
 
Figure 2. The antifungal effect of L. sericata nES on fungal growth: The effect of incubating fungal 
strains in the presence of L. sericata nES was evaluated using the OD assay. A high level of antifungal 
activity was seen after nES treatment of C. albicans (A), with complete inhibition being observed in 
C. krusei (B), C. maltosa (C), S. boulardii (D) and S. cerevisiae (E). No inhibition of C. albicans was 
observed after treatment with L1 nES (F). 
 
Figure 3. Survival index of C. albicans after incubation with heat treated nES, calculated by the OD 
assay and SI. Antifungal activity of nES was not found to be adversely affected by heating, still 
retaining significant activity despite exposure to extreme temperatures. Following heat treatment, 
there was generally found to be a significant increase in activity, compared to untreated nES (n = 9, 
50OC for 30 minutes, n = 8). There was however no significant difference in activity seen in the nES 
fraction heated to 100OC for 15 minutes; * = P <0.05, ** = P <0.005, *** = P <0.001. Negative SI 
values represent a negative difference between samples t mid-log and t0. This reduction in 
absorbance was found to be within the accepted 4.4% confidence value. All SI values are relative to 
100% growth of the positive growth control. 
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Figure 4. Survival index of C. albicans after incubation with nES treated by 10 cycles of freezing and 
thawing and storage at room temperature, calculated by the OD assay and SI. There was found to 
be no significant difference in antifungal activity in nES samples which had been subjected to 10 
cycles of freezing and thawing (n = 8) or storage at room temperature for up to seven days (n = 9). 
However, a statistically significant increase in antifungal activity was seen in samples which had been 
incubated for 14 days at room temperature (P <0.001, n = 9). All SI values are relative to 100% 
growth of the positive growth control. 
 
Figure 5. Effects of L. sericata nES and its fractions on Candida and Saccharomyces spp growth. (A) 
Survival index of Candida and Saccharomyces spp during incubation with nES and its fractions, 
calculated by the OD assay and SI. Both nES and its fractions possess strong antifungal properties, as 
indicated by the low SI across all fractions and fungal species tested compared to 100% growth of 
the positive growth control. There was also found to be a very highly significant difference in fungal 
growth of the positive control (100%) and fungi treated with ES fractions (P <0.001, n = ≥6). A high 
level of sensitivity was seen by C. albicans against ES>10 and ES10-0.5 fractions (B), as well as ES<0.5 (C). 
 
Figure 6. Survival index of C. albicans after incubation with treated ES<0.5, determined by the OD 
assay and SI. As seen with nES, heating, freeze/thawing, storage at room temperature for 14 days  
and lyophilisation appeared to have no significant negative effect on the antifungal activity of L. 
sericata ES<0.5. Negative SI values represent a negative difference between samples t mid-log and t0. 
This reduction in absorbance was found to be within the accepted 4.4% confidence value on two 
occasions. All SI values are relative to 100% growth of the positive growth control. 
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Supplementary material figure 1. Survival index of C. albicans during incubation with nES and its 
fractions, calculated by the OD assay and SI. Neither L1 nES nor any of its fractions were found to 
possess antifungal properties, as indicated by the increased SI. P >0.05; n = 9.  
Supplementary material figure 2. C. albicans growth following incubation with L. sericata L1 ES 
fractions. Fungal sensitivity was not observed during incubation with ES>10 and ES10-0.5 fractions (A) or 
ES<0.5 (B). 
Supplementary material table 1. Activity of fungal species against commonly used antifungal 
agents.  
Table indicating activity of amphotericin B, azoles and the ES<0.5 maggot fraction against the fungal 
species tested (As S. boulardii is related to S. cerevisiae it was not included in the table): “+” 
antifungal activity; “-” no antifungal activity. (1) European committee on antimicrobial susceptibility 
testing, antifungal agents, Breakpoint tables for interpretation of MICs. Version 7.0, 2014. (2) 
Enache-Angoulvant, A., Hennequin, C, Invasive Saccharomyces infection: A comprehensive review. 
Clinical infectious diseases, 2005. 41: p1559-68. 
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Figure 1. Antifungal activity of L. sericata nES and its fractions assessed by means of the CFU 
assay. (A) Percentage growth of C. albicans following incubation with L. sericata nES, ES10-0.5 and ES<0.5 was 
found to be reduced, suggesting significant antifungal activity (P <0.05) as calculated by the CFU assay. 
Incubation of C. albicans with ES>10 however resulted in a significant increase in the number of CFUs; * = P 
<0.05, ** = P <0.005, *** = P <0.001; n = 9. (B) Positive growth control (normal <I>C. albicans colony 
growth). (C) CFU growth following incubation with nES. (D) CFU growth following incubation with the ES<0.5 
fraction.  
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Figure 2. The antifungal effect of L. sericata nES on fungal growth: The effect of incubating fungal 
strains in the presence of L. sericata nES was evaluated using the OD assay. A high level of antifungal 
activity was seen after nES treatment of C. albicans (A), with complete inhibition being observed in C. krusei 
(B), C. maltosa (C), S. boulardii (D) and S. cerevisiae (E). No inhibition of C. albicans was observed after 
treatment with L1 nES (F).  
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Figure 3. Survival index of C. albicans after incubation with heat treated nES, calculated by the 
OD assay and SI. Antifungal activity of nES was not found to be adversely affected by heating, still 
retaining significant activity despite exposure to extreme temperatures. Following heat treatment, there was 
generally found to be a significant increase in activity, compared to untreated nES (n = 9, 50OC for 30 
minutes, n = 8). There was however no significant difference in activity seen in the nES fraction heated to 
100OC for 15 minutes; * = P <0.05, ** = P <0.005, *** = P <0.001. Negative SI values represent a 
negative difference between samples t mid-log and t0. This reduction in absorbance was found to be within 
the accepted 4.4% confidence value. All SI values are relative to 100% growth of the positive growth 
control.  
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Figure 4. Survival index of C. albicans after incubation with nES treated by 10 cycles of freezing 
and thawing and storage at room temperature, calculated by the OD assay and SI. There was found 
to be no significant difference in antifungal activity in nES samples which had been subjected to 10 cycles of 
freezing and thawing (n = 8) or storage at room temperature for up to seven days (n = 9). However, a 
statistically significant increase in antifungal activity was seen in samples which had been incubated for 14 
days at room temperature (P <0.001, n = 9). All SI values are relative to 100% growth of the positive 
growth control.  
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Figure 5. Effects of L. sericata nES and its fractions on Candida and Saccharomyces spp growth. 
(A) Survival index of Candida and Saccharomyces spp during incubation with nES and its fractions, 
calculated by the OD assay and SI. Both nES and its fractions possess strong antifungal properties, as 
indicated by the low SI across all fractions and fungal species tested compared to 100% growth of the 
positive growth control. There was also found to be a very highly significant difference in fungal growth of 
the positive control (100%) and fungi treated with ES fractions (P <0.001, n = ≥6). A high level of 
sensitivity was seen by C. albicans against ES>10 and ES10-0.5 fractions (B), as well as ES<0.5 (C).  
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Figure 6. Survival index of C. albicans after incubation with treated ES<0.5, determined by the OD 
assay and SI. As seen with nES, heating, freeze/thawing, storage at room temperature for 14 days and 
lyophilisation appeared to have no significant negative effect on the antifungal activity of L. sericata ES<0.5. 
Negative SI values represent a negative difference between samples t mid-log and t0. This reduction in 
absorbance was found to be within the accepted 4.4% confidence value on two occasions. All SI values are 
relative to 100% growth of the positive growth control.  
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Supplementary Methodology 
Collections of larval secretions. 
Briefly, larvae were transferred from petri dishes to cell culture flasks and incubated with a small 
volume (200 µl/g
-1
 of larvae) of sterile Milli-Q ultrapure water (Millipore UK Ltd., Herefordshire, UK) 
in darkness for one hour at 30
O
C. ES were then collected from the larvae under sterile conditions in a 
class 2 fume hood (Nuaire, Caerphily, UK) and centrifuged at 10,000 g for 5 minutes to remove 
particulates. The supernatant was then retained as native ES (nES) and stored at -20
O
C until required 
for testing. For collection of first instar larval ES (hereafter referred to as L1 ES), 400 µl of sterile 
Milli-Q ultrapure water/g
-1
 of eggs were added to each vial after saline had been removed. Eggs 
were then incubated at 30
O
C and upon hatching, were incubated for a further hour. Collection and 
treatment of L1 ES took place as previously described. 
Optical density (OD) assay for the detection of antifungal activity. 
Fungi were grown and prepared for testing as previously described. A single colony of cultured fungi 
was suspended in 300 µl sterile Milli-Q water and mixed for 15 seconds on a vortex mixer. The cell 
density was then adjusted to 5 x 10
6
 cells/ml and a working fungal suspension prepared by further 
diluting this suspension x100. Fifty µl of 4x concentrated Sabouraud dextrose broth (SDB), prepared 
in 80 mM HEPES, pH 8.5, was added into the wells of a sterile, flat bottom 96-well plate to give a 
final concentration of 1x concentrated Sabouraud dextrose broth (SDB) in 20 mM HEPES. Four µl of 
working fungal suspension was then inoculated into each well and 146 µl of each ES sample was 
then added to give a final volume of 200 µl per well. Plates were then incubated at 30
O
C in a 
Thermoscan FC plate reader (Thermo Fisher Scientific Inc., Loughborough, UK) for between 30 and 
45 hours (depending on species tested) to obtain optimum growth curves demonstrating all phases 
of growth up to stationary phase, with the optical density at 550 (OD550) being measured hourly 
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following 10 seconds agitation. All readings were blanked against time zero to account for 
differences in the starting opacity. 
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Supplementary material figure 1. Survival index of C. albicans during incubation with nES and its 
fractions, calculated by the OD assay and SI. Neither L1 nES nor any of its fractions were found to 
possess antifungal properties, as indicated by the increased SI. P >0.05; n = 9.  
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Supplementary material figure 2. C. albicans growth following incubation with L. sericata L1 ES 
fractions. Fungal sensitivity was not observed during incubation with ES>10 and ES10-0.5 fractions (A) or 
ES<0.5 (B).  
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Supplementary material table 1. Activity of fungal species against commonly used antifungal 
agents. Table indicating activity of amphotericin B, azoles and the ES<0.5 maggot fraction against the fungal 
species tested (As S. boulardii is related to S. cerevisiae it was not included in the table): “+” antifungal 
activity; “-” no antifungal activity. (1) European committee on antimicrobial susceptibility testing, antifungal 
agents, Breakpoint tables for interpretation of MICs. Version 7.0, 2014. (2) Enache-Angoulvant, A., 
Hennequin, C, Invasive Saccharomyces infection: A comprehensive review. Clinical infectious diseases, 
2005. 41: p1559-68.  
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